GWG Holdings’ Insurtech Subsidiary, Life Epigenetics, Announces Two Major Insurers to Test Lifespan-Predictive Technology
October 03 2017 - 8:30AM
Life Epigenetics, the insurtech subsidiary of GWG Holdings,
Inc. (Nasdaq:GWGH), announced that two major life insurance
companies will begin pilot programs to test its epigenetic-based
M-Panel technology.
The pilots, developed in partnership with two
life insurance companies, are designed to explore how the M-Panel
predictive epigenetic technology can be best applied to insurance
products and services. As part of scaling up its operational
capabilities, Life Epigenetics has set up a global network of
suppliers and test facilities that enable it to analyze tens of
thousands of saliva samples per month. And, Life Epigenetics has
established research partnerships with two major universities.
Life Epigenetics holds the exclusive license for
lifespan-predictive technology developed at the University of
California, Los Angeles (UCLA) for the life insurance industry.
Since February the company has been collecting and analyzing data
from life insurance policyholders. The pilot programs with the two
life insurance companies are intended to demonstrate new ways
epigenetic data can be used to improve underwriting efficiency and
precision.
“We are excited to announce these first steps in
the process of commercializing our technology for the global life
insurance industry,” said Jon Sabes, Life Epigenetics Chief
Executive Officer. “We believe we are now in position to create
breakthrough efficiencies for life insurance companies in terms of
improving the precision of their underwriting.”
Life Epigenetics is discussing its work with
major life insurance and reinsurance companies that have expressed
interest in learning more about how the technology can add value to
their businesses. “We have been pleased that our work has not gone
unnoticed by life insurance companies around the world,” Sabes
said.
Under the direction of Life Epigenetics’ Chief
Science Officer Dr. Brian Chen, Life Epigenetics has continued
research into the “DNA methylation-based predictor of mortality
technology” developed by Dr. Steve Horvath at UCLA. Dr. Chen is
first author in Dr. Horvath’s original research on the mortality
predictor and the biological clock.
About Life Epigenetics
Life Epigenetics is the insurtech subsidiary of
GWG Holdings, Inc. (Nasdaq:GWGH) that is dedicated to creating new
technology that is transformative to the way life insurance and
financial services underwrite and deliver longevity-based products
and services. The company’s “DNA methylation-based predictor of
mortality technology,” exclusively licensed from the University of
California, Los Angeles (UCLA), provides unprecedented new insight
into longevity using the cutting edge science of epigenetics.
For more information about Life Epigenetics,
Inc., visit www.lifeegx.com
About GWG Holdings, Inc.
GWG Holdings, Inc. (Nasdaq:GWGH) is a financial
services company committed to transforming the life insurance
industry through disruptive and innovative products and services.
The company owns Life Epigenetics and GWG Life. GWG Life is
developing a suite of new longevity-based products for consumers
and financial advisors under the LifeCare Xchange (LCX). The
LifeCare Xchange provides consumers owning life insurance with the
opportunity to exchange their life insurance into products that can
be used to pay for long-term care and meet other retirement
financial needs. Life Epigenetics is developing transformative
M-Panel epigenetic technology to disrupt traditional life insurance
underwriting practices. Since 2006, GWG Life has provided seniors
over $436 million in exchange value for their life insurance and,
as of June 30, 2017, owns a portfolio of over $1.5 billion in face
value of policy benefits.
For more information about GWG Holdings, Inc.
email info@gwglife.com or visit www.gwgh.com.
Media Contact:
Dan Callahan Director of Communication GWG Holdings, Inc. (612)
746-1935 dcallahan@gwglife.com
GWG (NASDAQ:GWGH)
Historical Stock Chart
From Aug 2024 to Sep 2024
GWG (NASDAQ:GWGH)
Historical Stock Chart
From Sep 2023 to Sep 2024